

India Contract Development and Manufacturing Organization (CDMO) Market Report and Forecast 2025-2034

Market Report | 2025-06-20 | 250 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2789.00
- Five User License \$3909.00
- Corporate License \$5099.00

Report description:

The India contract development and manufacturing organization (CDMO) market was valued at USD 23.02 Billion in 2024 driven by large pool of skilled scientists, cost-effective manufacturing capabilities, and a well-established generic and biosimilars industry across the region. It is expected to grow at a CAGR of 10.80% during the forecast period of 2025-2034 and attain a market value of USD 64.20 Billion by 2034. In addition, the rising demand for complex biologics, global expansion strategies by Indian CDMOs, and increasing collaborations are driven by regulatory alignment with major markets like the U.S. and EU.

Indian CDMOs benefit from a long history in generic drug manufacturing, which has shaped a workforce skilled in process optimization, scale-up, and regulatory compliance. That foundation is now being applied to more advanced services, including biologics, cell and gene therapies, and niche formulations like antibody-drug conjugates (ADCs). As global demand for these therapies grows, Indian firms are investing in high-containment facilities, single-use bioreactors, and integrated R&D platforms to support the shift.

India Contract Development and Manufacturing Organization (CDMO) Market Overview

Contract development and manufacturing organizations (CDMOs) play a vital role in India's pharmaceutical and medical device industries by offering end-to-end services from research and development to commercial-scale manufacturing. They enable companies to reduce operational costs, accelerate product development, and comply with stringent global regulatory standards. With India's strong manufacturing capabilities, skilled workforce, and supportive policies, CDMOs attract both domestic and international clients. Their presence enhances innovation, efficiency, and global competitiveness, significantly contributing to the growth of India's life sciences sector. The market is expected to grow at a CAGR of 10.80% during the forecast period of 2025-2034 and attain a market value of USD 64.20 Billion by 2034.

What are the Drivers for India Contract Development and Manufacturing Organization (CDMO) Market Growth?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Programs Based on Strengthening India's Clinical Research and CDMO Capabilities to Boost Market Growth

In February 2025, Avance Clinical, an Australian CRO, established a specialized biometrics hub in Bangalore to enhance its GlobalReady program. This expansion focuses on statistical programming and data analytics to accelerate early-phase clinical trials for biotech companies in the United States and Australia. As demand for outsourced clinical research rises and India remains a hub for skilled talent and cost-effective services, this move is expected to elevate India's global standing in the CRO and CDMO markets during the forecast period.

Biologics Manufacturing Advancements to Meet Rising India Contract Development and Manufacturing Organization (CDMO) Market Demand

In January 2025, Shilpa Biologicals inaugurated a new bioconjugation manufacturing facility in Karnataka (a Southern state in India), joining the global league of CDMOs offering integrated antibody-drug conjugate (ADC) capabilities. This complements its existing cytotoxic fill-finish site in Hyderabad and positions India as a growing hub for complex biologics manufacturing. With increasing demand for high-quality, cost-efficient biologics production, such infrastructure upgrades are expected to attract international partnerships and boost the growth and global competitiveness of India's CDMO market.

What are the India Contract Development and Manufacturing Organization (CDMO) Market Trends?

The major market trends in the Indian CDMO market include rising global acquisitions and hybrid manufacturing models, enhancing value and development of the market.

Strategic Global Acquisitions Boosting India Contract Development and Manufacturing Organization (CDMO) Market Value

In June 2025, Zydus Lifesciences announced its entry into the global biologics CDMO sector with plans to acquire Agenus Inc.'s manufacturing facilities in the United States. The move allows Zydus to scale biologics production and enhance its global service capabilities. As Indian CDMOs increasingly pursue international acquisitions, such strategies are poised to elevate India's market value and global competitiveness in high-margin biologics outsourcing.

Hybrid CDMO Innovations Strengthening India Contract Development and Manufacturing Organization (CDMO) Market Size

In March 2024, Shilpa Medicare launched a new hybrid CDMO platform in New York. The model integrated development and commercial-scale manufacturing across biologics, synthetic small molecules, and complex generics. This aligns with India's growing focus on end-to-end CDMO solutions that meet global regulatory standards. The hybrid approach is expected to attract international partnerships, drive operational efficiency, and significantly strengthen India's CDMO market development during the forecast period.

What is the India Contract Development and Manufacturing Organization (CDMO) Market Segmentation?

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Service Type

- CRO

??- Clinical Services Preclinical Phase I Phase II Phase III Phase IV

??- Laboratory Services Analytical Services Bioanalytical Services

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

??- Chemistry, manufacturing and Controls (CMC)

??- Others

- CMO

??- Finished Dosage Formulation (FDF) Development and Manufacturing Solid Dose Formulation Liquid Dose Formulation
Injectable Dose Formulation

??- Active Pharmaceutical Ingredient (API) Manufacturing High Potency (HPAPI) Large Molecule Small Molecule

Market Breakup by Application

- Oncological Disease
- Cardiovascular Disease
- Infectious Disease
- Others

Market Breakup by Region

- North India
- East and Central India
- West India
- South India

India Contract Development and Manufacturing Organization (CDMO) Market Share

Oncological Diseases to Lead the Market Share by Application

Oncological diseases are projected to hold the largest market share in India's contract development and manufacturing organization (CDMO) sector due to the escalating cancer burden and the growing demand for advanced therapeutics. In 2022, India reported approximately 1.46 million new cancer cases, with projections indicating an increase to 1.57 million by 2025, reflecting a 12.8% rise over five years. This surge underscores the urgent need for innovative cancer treatments. India's robust capabilities in developing and manufacturing complex generics, biosimilars, and antibody-drug conjugates attract global pharmaceutical companies seeking cost-effective oncology drug development. As per the analysis by Expert Market Research, the India biosimilar market is expected to grow at a CAGR of 14.20% during the forecast period of 2025-2034. In contrast, while cardiovascular and infectious diseases also contribute significantly, the complexity, investment, and innovation in oncology drug pipelines continue to drive the segment's dominance through the forecast period.

Who are the Leading Players in the India Contract Development and Manufacturing Organization (CDMO) Market?

The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Syngene International Limited

Established in 1993 and headquartered in Bangalore, India, Syngene International Limited is a leading contract research, development, and manufacturing organization (CRDMO). It offers integrated services across the drug development value chain, including discovery chemistry, biology, safety assessment, and commercial manufacturing. Syngene caters to global

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

pharmaceutical, biotechnology, and agrochemical companies. Its state-of-the-art facilities and collaborations with major multinationals such as Bristol Myers Squibb reinforce its position as a key player in India's CDMO ecosystem.

Piramal Pharma Ltd.

Piramal Pharma Ltd., headquartered in Mumbai and established in 1988, is a global pharmaceutical company offering end-to-end contract development and manufacturing services. Through its CDMO division, Piramal Pharma Solutions, it supports drug substance and drug product development for small and large molecules. The company's portfolio spans clinical trial supply, API manufacturing, and sterile fill-finish. With facilities across North America, Europe, and India, Piramal is recognized for its regulatory compliance and scalable manufacturing capabilities.

Divi's Laboratories Ltd.

Founded in 1990 and headquartered in Hyderabad, Divi's Laboratories Ltd. is one of India's largest pharmaceutical manufacturing firms, focused on APIs, intermediates, and custom synthesis. With strong capabilities in complex chemistry and large-scale production, Divi's serves leading global pharma companies as a trusted CDMO partner. The company operates world-class manufacturing facilities and maintains high compliance with international regulatory standards, making it a major contributor to India's prominence in outsourced pharmaceutical development.

Laurus Synthesis Private Limited

Laurus Synthesis Private Limited, a subsidiary of Laurus Labs headquartered in Hyderabad and established in 2022, offers specialized contract research and manufacturing services. It focuses on custom synthesis, process development, and manufacturing of niche APIs and intermediates. With capabilities in high-potency APIs and complex chemistry, Laurus Synthesis supports early to late-stage development for pharmaceutical companies. The company's scientific expertise, regulatory focus, and modern infrastructure position it as a rising player in India's CDMO landscape.

Other key players in the market include Jubilant Pharmova Limited Company, Thermo Fisher Scientific Inc. (Patheon Pharma Services), Lonza Group AG, WuXi STA, AGC Biologics, Pfizer, Inc., and PCI Pharma Services.

Key Questions Answered in the India Contract Development and Manufacturing Organization (CDMO) Market

- What was the India contract development and manufacturing organization (CDMO) market value in 2024?
- What is the India contract development and manufacturing organization (CDMO) market forecast outlook for 2025-2034?
- What are the major factors aiding the India contract development and manufacturing organization (CDMO) market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major India contract development and manufacturing organization (CDMO) market trends?
- Which service type will lead the market segment?
- Which application will lead the market segment?
- Who are the key players involved in the India contract development and manufacturing organization (CDMO) market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Table of Contents:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1	Preface
1.1	Objectives of the Study
1.2	Key Assumptions
1.3	Report Coverage - Key Segmentation and Scope
1.4	Research Methodology
2	Executive Summary
3	Contract Development and Manufacturing Organization (CDMO) Market Overview
3.1	Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market
3.1.1	Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Historical Value (2018-2024)
3.1.2	Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Forecast Value (2025-2034)
3.2	India Contract Development and Manufacturing Organization (CDMO) Market
3.2.1	India Contract Development and Manufacturing Organization (CDMO) Market Historical Value (2018-2024)
3.2.2	India Contract Development and Manufacturing Organization (CDMO) Market Forecast Value (2025-2034)
4	India Contract Development and Manufacturing Organization (CDMO) Market Landscape
4.1	India Contract Development and Manufacturing Organization (CDMO) Market: Developers Landscape
4.1.1	Analysis by Year of Establishment
4.1.2	Analysis by Company Size
4.1.3	Analysis by Region
4.2	India Contract Development and Manufacturing Organization (CDMO) Market: Service Landscape
4.2.1	Analysis By Service Type
4.2.2	Analysis By Application
5	India Contract Development and Manufacturing Organization (CDMO) Market Dynamics
5.1	Market Drivers and Constraints
5.2	SWOT Analysis
5.2.1	Strengths
5.2.2	Weaknesses
5.2.3	Opportunities
5.2.4	Threats
5.3	PESTEL Analysis
5.3.1	Political
5.3.2	Economic
5.3.3	Social
5.3.4	Technological
5.3.5	Legal
5.3.6	Environment
5.4	Porter's Five Forces Model
5.4.1	Bargaining Power of Suppliers
5.4.2	Bargaining Power of Buyers
5.4.3	Threat of New Entrants
5.4.4	Threat of Substitutes
5.4.5	Degree of Rivalry
5.5	Key Demand Indicators
5.6	Key Price Indicators
5.7	Industry Events, Initiatives, and Trends
5.8	Value Chain Analysis
6	India Contract Development and Manufacturing Organization (CDMO) Market Segmentation (218-2034)
6.1	India Contract Development and Manufacturing Organization (CDMO) Market (2018-2034) by Service Type

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1.1 Market Overview
- 6.1.2 CRO
 - 6.1.2.1 Clinical Services
 - 6.1.2.1.1 Preclinical
 - 6.1.2.1.2 Phase I
 - 6.1.2.1.3 Phase II
 - 6.1.2.1.4 Phase III
 - 6.1.2.1.5 Phase IV
 - 6.1.2.2 Laboratory Services
 - 6.1.2.2.1 Analytical Services
 - 6.1.2.2.2 Bioanalytical Services
 - 6.1.2.3 Chemistry, manufacturing and Controls (CMC)
 - 6.1.2.4 Others
- 6.1.3 CMO
 - 6.1.3.1 Finished Dosage Formulation (FDF) Development and Manufacturing
 - 6.1.3.1.1 Solid Dose Formulation
 - 6.1.3.1.2 Liquid Dose Formulation
 - 6.1.3.1.3 Injectable Dose Formulation
 - 6.1.3.2 Active Pharmaceutical Ingredient (API) Manufacturing
 - 6.1.3.2.1 High Potency (HPAPI)
 - 6.1.3.2.2 Large Molecule
 - 6.1.3.2.3 Small Molecule
- 6.2 India Contract Development and Manufacturing Organization (CDMO) Market (2018-2034) by Application
 - 6.2.1 Market Overview
 - 6.2.2 Oncological Disease
 - 6.2.3 Cardiovascular Disease
 - 6.2.4 Infectious Disease
 - 6.2.5 Others
- 6.3 India Contract Development and Manufacturing Organization (CDMO) Market (2018-2034) by Region
 - 6.3.1 Market Overview
 - 6.3.2 North India
 - 6.3.3 East and Central India
 - 6.3.4 West India
 - 6.3.5 South India
- 7 Regulatory Framework
- 8 Funding and Investment Analysis
 - 8.1 Analysis by Funding Instances
 - 8.2 Analysis by Type of Funding
 - 8.3 Analysis by Funding Amount
 - 8.4 Analysis by Leading Players
 - 8.5 Analysis by Leading Investors
 - 8.6 Analysis by Geography
- 9 Strategic Initiatives
 - 9.1 Analysis by Partnership Instances
 - 9.2 Analysis by Type of Initiatives
 - 9.3 Analysis by Leading Players
 - 9.4 Analysis by Geography

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10 Supplier Landscape
- 10.1 Market Share Analysis (Top 5 Companies)
- 10.2 Syngene International Limited
 - 10.2.1 Financial Analysis
 - 10.2.2 Service Portfolio
 - 10.2.3 Demographic Reach and Achievements
 - 10.2.4 Company News and Developments
 - 10.2.5 Certifications
- 10.3 Piramal Pharma Ltd.
 - 10.3.1 Financial Analysis
 - 10.3.2 Service Portfolio
 - 10.3.3 Demographic Reach and Achievements
 - 10.3.4 Company News and Developments
 - 10.3.5 Certifications
- 10.4 Divi's Laboratories Ltd.
 - 10.4.1 Financial Analysis
 - 10.4.2 Service Portfolio
 - 10.4.3 Demographic Reach and Achievements
 - 10.4.4 Company News and Developments
 - 10.4.5 Certifications
- 10.5 Laurus Synthesis Private Limited
 - 10.5.1 Financial Analysis
 - 10.5.2 Service Portfolio
 - 10.5.3 Demographic Reach and Achievements
 - 10.5.4 Company News and Developments
 - 10.5.5 Certifications
- 10.6 Jubilant Pharmova Limited Company
 - 10.6.1 Financial Analysis
 - 10.6.2 Service Portfolio
 - 10.6.3 Demographic Reach and Achievements
 - 10.6.4 Company News and Developments
 - 10.6.5 Certifications
- 10.7 Thermo Fisher Scientific Inc. (Patheon Pharma Services)
 - 10.7.1 Financial Analysis
 - 10.7.2 Service Portfolio
 - 10.7.3 Demographic Reach and Achievements
 - 10.7.4 Company News and Developments
 - 10.7.5 Certifications
- 10.8 Lonza Group AG
 - 10.8.1 Financial Analysis
 - 10.8.2 Service Portfolio
 - 10.8.3 Demographic Reach and Achievements
 - 10.8.4 Company News and Developments
 - 10.8.5 Certifications
- 10.9 WuXi STA
 - 10.9.1 Financial Analysis
 - 10.9.2 Service Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.9.3 Demographic Reach and Achievements
- 10.9.4 Company News and Developments
- 10.9.5 Certifications
- 10.10 AGC Biologics
 - 10.10.1 Financial Analysis
 - 10.10.2 Service Portfolio
 - 10.10.3 Demographic Reach and Achievements
 - 10.10.4 Company News and Developments
 - 10.10.5 Certifications
- 10.11 PCI Pharma Services
 - 10.11.1 Financial Analysis
 - 10.11.2 Service Portfolio
 - 10.11.3 Demographic Reach and Achievements
 - 10.11.4 Company News and Developments
 - 10.11.5 Certifications
- 10.12 Pfizer, Inc.
 - 10.12.1 Financial Analysis
 - 10.12.2 Service Portfolio
 - 10.12.3 Demographic Reach and Achievements
 - 10.12.4 Company News and Developments
 - 10.12.5 Certifications
- 11 Contract Development and Manufacturing Organization (CDMO) Market - Distribution Model (Additional Insight)
 - 11.1 Overview
 - 11.2 Potential Distributors
 - 11.3 Key Parameters for Distribution Partner Assessment
- 12 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 13 Payment Methods (Additional Insight)
 - 13.1 Government Funded
 - 13.2 Private Insurance
 - 13.3 Out-of-Pocket

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

India Contract Development and Manufacturing Organization (CDMO) Market Report and Forecast 2025-2034

Market Report | 2025-06-20 | 250 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2789.00
	Five User License	\$3909.00
	Corporate License	\$5099.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com